Transgenomic Q2 Revenues Drop 7 Percent | GenomeWeb

NEW YORK (GenomeWeb) — Transgenomic said after the close of the market on Wednesday that its second quarter revenues declined 7 percent year over year.

For the three months ended June 30, the Omaha, Neb.-based company reported $6.8 million in revenues compared to $7.3 million in the same quarter last year. Transgenomic said this decline was attributable to a $300,000 decrease in its Genetic Assays and Platforms segment due to fewer instrument sales, and a $200,000 drop in Laboratory Services revenues due to lower sales of contract development services to pharmaceutical clients.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.

Mar
02
Sponsored by
VelaDx

This online seminar will highlight recent advances in the use of next-generation sequencing to detect drug-resistant mutations in patients with HIV or HCV.